A Study of IBI362 in Participants With Type 2 Diabetes
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 731 participants.
Also called NCT05606913
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; double masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 731 participants
- Registry
-
NCT05606913
-
- Other papers using this trial's data
- Mazdutide versus dulaglutide in Chinese adults with type 2 diabetes
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- China
- Registry status
- Completed
Technical summary
Registry record NCT05606913. Randomized; double masking; primary purpose treatment. Start 2023-01-06 (actual); primary completion 2024-01-26 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study of IBI362 in Participants With Type 2 Diabetes
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- dulaglutide
- Intervention (Drug)
- IBI362
- Lead sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
Record details
- Record id
cardio:ct-nct05606913- Content hash
4b4c0f53c943300b402f7ec1f2d708d66df1f8e04694ac57f6f8696c1b7d661b